Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 187

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part II, Item 1A
Chunk 187
---
 in such patents being narrowed, invalidated or held unenforceable;

•the third-party licensor may fail to obtain or lose patent protection for new vaccine candidates or technology or issued patents claiming the vaccine candidates or technology may expire, which could impact our competitive position; or

•we may not be able to realize the anticipated benefits of or successfully integrate with our existing business any new vaccine candidates or technology.

If we are unable to successfully develop, obtain regulatory approval for, or commercialize new vaccine candidates, or if any related agreements are terminated, our business, financial condition, and results of operations could be materially and adversely affected.

64

We cannot ensure that we will be successful in selecting, executing and integrating any programs or technologies. Failure to manage and successfully develop these programs or technologies could materially harm our business and operating results. In addition, if stock market analysts or our stockholders do not support or believe in the value of the transactions or arrangements that we choose to undertake, or the vaccine candidates or technologies we choose to pursue, our stock price may decline.

In connection with these strategic arrangements, we could make investments to further our strategic objectives and support our key business initiatives. For example, as part of our license agreement with Vaxart we have made a strategic investment in Vaxart’s common stock. If any company in which we invest fails, we could lose all or part of our investment in that company. If we determine that an other-than-temporary decline in the fair value exists for an equity or debt investment in a public or private company in which we have invested, we will have to write down the investment to its fair value and recognize the related write-down as an investment loss. The performance of any of these investments could result in significant impairment charges and gains (losses) on other equity investments. 

We must also analyze accounting and legal issues when making these investments. Such transactions or arrangements may result in complex accounting and disclosure requirements. These requirements could include the potential consolidation of another party’s financial results into our own. Such consolidation or other intricate accounting treatments may increase the complexity of our financial statements, making them more difficult for investors and other stakeholders to analyze and interpret. If we fail to accurately apply these requirements or effectively communicate the resulting impacts, we could face regulatory scrutiny, restatements, or reputational harm, which may adversely affect our financial condition and the market price of our securities.

Furthermore, we may seek to dispose of an investment from time to time. If our equity investments are not liquid, we may not be able